Biological therapy for ulcerative colitis

Gastroenterology Report

Volumn 3, Issue 2, 2015, Pages 103-109

  Arora, Zubin ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anti integrin agents; Biological therapy; TNF antagonists; Ulcerative colitis

Indexed keywords

EID: 84990252439     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gou070     Document Type: Review

References (74)

1. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42.
2. Danese S and Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25.
3. Sands BE and Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol 2007;47:930-41.
4. Owczarek D, Cibor D, Szczepanek M et al. Biological therapy of inflammatory bowel disease. Pol Arch Med Wewn 2009;119:84-8.
5. Sandborn WJ and Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-33.
6. Rutgeerts P, Vermeire S and Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-97.
7. Murch SH, Braegger CP, Walker-Smith JA et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
8. Masuda H, Iwai S, Tanaka T et al. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995;46:111-23.
9. Nielsen OH, Gionchetti P, Ainsworth M et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94:2923-8.
10. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for in-duction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
11. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
12. Ochsenkühn T, Sackmann Mand Göke B.Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16:1167-71.
13. Probert CSJ, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a rand-omised controlled trial. Gut 2003;52:998-1002.
14. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8.
15. Bermejo F, López-Sanroman A, Hinojosa J et al. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004;96:94-101.
16. Armuzzi A, De Pascalis B, Lupascu A et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 8:231-3.
17. Gornet JM, Couve S, Hassani Z et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label mul-ticentre study. Aliment Pharmacol Ther 2003;18:175-81.
18. Actis GC, Bruno M, Pinna-Pintor M et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34:631-4.
19. Kohn A, Prantera C, Pera A et al. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34:626-30.
20. Kaser A, Mairinger T, Vogel W et al. Infliximab in severe ste-roid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001;113:930-3.
21. Schroeder KW, Tremaine WJ and Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
22. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.
23. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
24. Yeates J and Rashid M. Successful long-term use of infliximab in refractory pouchitis in an adolescent. Gastroenterol Res Pract 2010;2010:860394.
25. Calabrese C, Gionchetti P, Rizzello F et al. Short-term treat-ment with infliximab in chronic refractory pouchitis and ilei-tis. Aliment Pharmacol Ther 2008;27:759-64.
26. Ferrante M, D'Haens G, Dewit O et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis 2010;16:243-9.
27. Barreiro-de Acosta M, García-Bosch O, Souto R et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012;18:812-17.
28. Viazis N, Giakoumis M, Koukouratos T et al. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis 2013;7:e457-60.
29. Viscido A, Habib FI, Kohn A et al. Infliximab in refractory pou-chitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003;17:1263-71.
30. Molnar T, Farkas K, Nagy F et al. Successful use of infliximab for treating fistulizing pouchitis with severe extraintestinal manifestation: a case report. Inflamm Bowel Dis 2008;14:1752-3.
31. Colombel JF, Ricart E, Loftus EV et al. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003;98:2239-44.
32. Barreiro-de Acosta M, Lorenzo A and Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009;15:3814-16.
33. Armuzzi A, Biancone L, Daperno M et al. Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis 2013;45:738-43.
34. Afif W, Leighton JA, Hanauer SB et al. Open-label study of ada-limumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7.
35. Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3.
36. Oussalah A, Laclotte C, Chevaux J-B et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72.
37. Gies N, Kroeker KI, Wong K et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a sin-gle-centre cohort. Aliment Pharmacol Ther 2010;32:522-8.
38. Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7.
39. Colombel JF, Sandborn WJ, Wolf D et al. PTU-055 long-term ef-ficacy of adalimumab for treatment of moderately to severely active ulcerative colitis. Gut 2013;62:A66-7.[Abstract]
40. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous goli-mumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95.
41. Sandborn WJ, Feagan BG, Marano C et al. Subcutaneous golimu-mab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109.e1.
42. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38.
43. Goel N and Stephens S. Certolizumab pegol. MAbs 2010;2:137-47.
44. Palframan R, Airey M, Moore A et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41.
45. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32.
46. Stephens S, Brown D, Nesbitt A et al. P152 lack of placental transfer and accumulation in milk of an anti-TNF pegylated Fab' fragment in rats. J Crohn's Colitis Suppl 2007;1:43. [Abstract]
47. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50.
48. Certolizumab pegol for the treatment of moderate-to-severe ulcerative colitis: an open-label study. Available at: http://clinicaltrials.gov/show/NCT01090154 [Accessed: 13 Oct. 2014]
49. Van Assche G and Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiad-hesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005;288:G169-74.
50. Löwenberg M and D'Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep 2013;15:311.
51. Jovani M and Danese S. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets 2013;14:1433-43.
52. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
53. FDA approves Entyvio to treat ulcerative colitis and Crohn's disease. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm398065.htm [Accessed: 13 Oct. 2014]
54. An open-label study of vedolizumab (MLN0002) in patients with ulcerative colitis and Crohn's disease (GEMINI LTS). Available at: http://clinicaltrials.gov/ct2/show/NCT00790933 [Accessed: 13 Oct. 2014]
55. Vermeire S, Ghosh S, Panes J et al. The mucosal addressin cell adhesion molecule antibody PF-00547, 659 in ulcerative colitis: a randomised study. Gut 2011;60:1068-75.
56. Vegter S, Tolley K, Wilson Waterworth T et al. Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2013;38:284-93.
57. Miner P, Wedel M, Bane B et al. An enema formulation of ali-caforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchi-tis. Aliment Pharmacol Ther 2004;19:281-6.
58. Lichtenstein GR and Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010;16:338-46.
59. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
60. Frøslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22.
61. Rutgeerts P, Vermeire S and Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-5.
62. Langholz E. Current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol 2010;3:77-86.
63. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60.
64. Gustavsson A, Järnerot G, Hertervig E et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis-3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010;32:984-9.
65. Feagan BG, Sandborn WJ, Lazar A et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014;146:110-18.e3.
66. Sandborn WJ, Van Assche GA, Thakkar R et al. Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis. Gastroenterology 2011;140:S263. [Abstract]
67. Hoentjen F and van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009;15:2067-73.
68. Van Assche G, Lewis JD, Lichtenstein GR et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011;106:1594-602.
69. Rahier JF, Chowers Y, Conlon C et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009;3:47-91.
70. D'Haens GR, Panaccione R, Higgins PDR et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011;106:199-212.
71. Wasan SK, Baker SE, Skolnik PR et al. A practical guide to vac-cinating the inflammatory bowel disease patient. Am J Gastroenterol 2010;105:1231-8.
72. Mason M and Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis 2013;19:1306-21.
73. Vermeire S, Noman M, Van Assche G et al. Autoimmunity as-sociated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-9.
74. Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.